Case number 1:23-cv-00272
Allergan, Inc. et al v. Mankind Pharma Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 29, 2023 | 42 | DECLARATION of Alan H. Pollack re 41 Reply Brief, by Mankind Pharma Ltd.. (Attachments: # 1 Exhibit 1)(Taylor, Daniel) Modified on 6/29/2023 (nms). (Entered: 06/29/2023) (Exhibit 1) (6) |
| Jun 29, 2023 | 42 | DECLARATION of Alan H. Pollack re 41 Reply Brief, by Mankind Pharma Ltd.. (Attachments: # 1 Exhibit 1)(Taylor, Daniel) Modified on 6/29/2023 (nms). (Entered: 06/29/2023) (Main Document) (1) |
| Jun 29, 2023 | 41 | [SEALED] REPLY BRIEF re 20 MOTION for Judgment on the Pleadings filed by Mankind Pharma Ltd.. (Attachments: # 1 Certificate of Service)(Taylor, Daniel) (Entered: 06/29/2023) (0) |
| Jun 14, 2023 | 40 | REDACTED VERSION of 38 Answering Brief in Opposition by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Exhibit A)(Tigan, Jeremy) (Entered: 06/14/2023) (Exhibit A) (11) |
| Jun 14, 2023 | 40 | REDACTED VERSION of 38 Answering Brief in Opposition by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Exhibit A)(Tigan, Jeremy) (Entered: 06/14/2023) (Main Document) (20) |
| Jun 12, 2023 | N/A | SO ORDERED, re 39 STIPULATION and Proposed Order (*Reset Briefing Schedule: re 20 MOTION for Judgment on the Pleadings. Reply Brief due 6/29/2023). Signed by Judge Richard G. Andrews on 6/12/2023. (nms) (Entered: 06/12/2023) (0) |
| Jun 9, 2023 | 39 | STIPULATION and Proposed Order - filed by Mankind Pharma Ltd.. (Taylor, Daniel) Modified on 6/9/2023 (nms). (Entered: 06/09/2023) (1) |
| Jun 8, 2023 | 38 | [SEALED] ANSWERING BRIEF in Opposition re 20 MOTION for Judgment on the Pleadings filed by AbbVie Inc., Allergan, Inc..Reply Brief due date per Local Rules is 6/15/2023. (Attachments: # 1 Exhibit A)(Blumenfeld, Jack) (Entered: 06/08/2023) (0) |
| Jun 2, 2023 | 37 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Federal Rule of Civil Procedure 26(a)(1)(A); (2) Plaintiffs' Paragraph 3 Initial Disclosures Regarding Discovery of Electronically Stored Information; and (3) Plaintiffs' Identification of Accused Product and Asserted Patent and Disclosure of Damages Model filed by AbbVie Inc., Allergan, Inc..(Blumenfeld, Jack) (Entered: 06/02/2023) (3) |
| Jun 2, 2023 | 36 | NOTICE OF SERVICE of Defendant Mankind Pharmaceuticals Limited's Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) and the Court's Default Standard for Discovery, Including Discovery of Electronically Stored Information ("ESI") Paragraph 3 filed by Mankind Pharma Ltd..(Taylor, Daniel) (Entered: 06/02/2023) (1) |
| May 23, 2023 | N/A | SO ORDERED, re 35 STIPULATION and Proposed Order (*Reset Briefing Schedule: re 20 MOTION for Judgment on the Pleadings. Answering Brief due 6/8/2023). Signed by Judge Richard G. Andrews on 5/23/2023. (nms) (Entered: 05/23/2023) (0) |
| May 23, 2023 | 35 | STIPULATION and Proposed Order - filed by AbbVie Inc., Allergan, Inc.. (Blumenfeld, Jack) Modified on 5/23/2023 (nms). (Entered: 05/23/2023) (1) |
| May 17, 2023 | N/A | SO ORDERED, re 34 MOTION for Pro Hac Vice Appearance of Attorney Michael A. Morin and David A. Frazier, filed by Allergan, Inc., AbbVie Inc.. Signed by Judge Richard G. Andrews on 5/17/2023. (nms) (Entered: 05/17/2023) (0) |
| May 17, 2023 | 34 | MOTION for Pro Hac Vice Appearance of Attorney Michael A. Morin and David A. Frazier - filed by AbbVie Inc., Allergan, Inc.. (Tigan, Jeremy) (Entered: 05/17/2023) (5) |
| May 9, 2023 | 33 | SO ORDERED Granting 32 Stipulated Protective Order. Signed by Judge Richard G. Andrews on 5/9/2023. (nms) (Entered: 05/09/2023) (29) |
| May 9, 2023 | 32 | PROPOSED Protective Order, by AbbVie Inc., Allergan, Inc.. (Blumenfeld, Jack) Modified on 5/9/2023 (nms). (Entered: 05/09/2023) (29) |
| May 5, 2023 | 31 | JOINT SCHEDULING ORDER: Joinder of Parties due by 9/25/2023. Amended Pleadings due by 9/25/2023. Fact Discovery completed by 7/16/2024. Expert Discovery due by 11/10/2024. Joint Claim Construction Brief due by 12/12/2023. A Markman Hearing is set for 1/10/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 1/3/2025, at 9:00 AM in Courtroom 6A. A 3-day Bench Trial is set to start 1/21/2025, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 5/5/2023. (nms) (Entered: 05/05/2023) (9) |
| May 5, 2023 | 30 | PROPOSED Scheduling Order, by AbbVie Inc., Allergan, Inc.. (Blumenfeld, Jack) Modified on 5/5/2023 (nms). (Entered: 05/05/2023) (11) |
| May 4, 2023 | 29 | REDACTED VERSION of 21 Opening Brief in Support, by Mankind Pharma Ltd.. (Taylor, Daniel) Modified on 5/4/2023 (nms). (Entered: 05/04/2023) (20) |
| May 4, 2023 | 28 | STIPULATION and Proposed Order - filed by AbbVie Inc., Allergan, Inc.. (Blumenfeld, Jack) Modified on 5/4/2023 (nms). (Entered: 05/04/2023) (1) |
| May 4, 2023 | N/A | SO ORDERED, re 28 STIPULATION and Proposed Order (*Reset Briefing Schedule: re 20 MOTION for Judgment on the Pleadings. Answering Brief due 5/25/2023). Signed by Judge Richard G. Andrews on 5/4/2023. (nms) (Entered: 05/04/2023) (0) |
| May 3, 2023 | 26 | ORAL ORDER: The redacted filing (D.I. 25 ) is REJECTED as it not a complete version of what was presented at D.I. 19 , the exhibits A-E are missing. A revised redacted filing is DUE within three business days. Ordered by Judge Richard G. Andrews on 5/3/2023. (nms) (Entered: 05/03/2023) (0) |
| May 3, 2023 | 27 | REDACTED VERSION of 19 Answer to Counterclaim by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Exhibits A-E)(Blumenfeld, Jack) (Entered: 05/03/2023) (Main Document) (25) |
| May 3, 2023 | 27 | REDACTED VERSION of 19 Answer to Counterclaim by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Exhibits A-E)(Blumenfeld, Jack) (Entered: 05/03/2023) (Exhibits A-E) (30) |
| May 2, 2023 | 25 | REDACTED VERSION of 19 Answer to Counterclaim by AbbVie Inc., Allergan, Inc.. (Blumenfeld, Jack) (Entered: 05/02/2023) (25) |
| May 1, 2023 | 24 | ORAL ORDER: In reference to the proposed scheduling order (D.I. 23 ), the trial date is Tuesday, January 21, 2025; the pretrial conference date is January 3, 2025 at 9 a.m.; and the claim construction hearing date is January 10, 2024 at 9 a.m. The parties ought to be able to resolve the remaining disputes without the Courts assistance. The conference on May 2 is cancelled. The parties are to submit a revised proposed scheduling order by May 5, 2023. Ordered by Judge Richard G. Andrews on 5/1/2023. (nms) (Entered: 05/01/2023) (0) |
| Apr 28, 2023 | 22 | NOTICE OF SERVICE of Mankind Pharma Limited's Core Technical Documents filed by Mankind Pharma Ltd..(Taylor, Daniel) (Entered: 04/28/2023) (1) |
| Apr 28, 2023 | 23 | PROPOSED Scheduling Order, by AbbVie Inc., Allergan, Inc.. (Tigan, Jeremy) Modified on 4/28/2023 (nms). (Entered: 04/28/2023) (12) |
| Apr 27, 2023 | 20 | MOTION for Judgment on the Pleadings - filed by Mankind Pharma Ltd.. (Attachments: # 1 Text of Proposed Order)(Taylor, Daniel) (Entered: 04/27/2023) (Main Document) (1) |
| Apr 27, 2023 | 21 | [SEALED] OPENING BRIEF in Support re 20 MOTION for Judgment on the Pleadings filed by Mankind Pharma Ltd..Answering Brief/Response due date per Local Rules is 5/11/2023. (Attachments: # 1 Certificate of Service)(Taylor, Daniel) (Entered: 04/27/2023) (0) |
| Apr 27, 2023 | 20 | MOTION for Judgment on the Pleadings - filed by Mankind Pharma Ltd.. (Attachments: # 1 Text of Proposed Order)(Taylor, Daniel) (Entered: 04/27/2023) (Text of Proposed Order) (1) |
| Apr 25, 2023 | 19 | [SEALED] ANSWER to 9 Answer to Complaint and Counterclaims, by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Exhibits A-E)(Blumenfeld, Jack) Modified on 4/25/2023 (nms). (Entered: 04/25/2023) (0) |
| Apr 12, 2023 | N/A | Pro Hac Vice Attorneys Alan H. Pollack, Andrew J. Miller for Mankind Pharma Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 04/12/2023) (0) |
| Apr 12, 2023 | 18 | STIPULATION and Proposed Order - filed by AbbVie Inc., Allergan, Inc.. (Blumenfeld, Jack) Modified on 4/12/2023 (nms). (Entered: 04/12/2023) (1) |
| Apr 12, 2023 | N/A | SO ORDERED, re 18 STIPULATION and Proposed Order (*Reset Answer Deadlines: AbbVie Inc. answer due 4/25/2023; Allergan, Inc. answer due 4/25/2023). Signed by Judge Richard G. Andrews on 4/12/2023. (nms) (Entered: 04/12/2023) (0) |
| Apr 11, 2023 | 16 | REDACTED VERSION of 9 Answer to Complaint and Counterclaims, by Mankind Pharma Ltd.. (Attachments: # 1 Exhibits A-C)(Belgam, Neal) Modified on 4/11/2023 (nms). (Entered: 04/11/2023) (Main Document) (26) |
| Apr 11, 2023 | 17 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 5/2/2023, at 10:00 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 4/11/2023. (nms) (Entered: 04/11/2023) (1) |
| Apr 11, 2023 | N/A | SO ORDERED, re 15 MOTION for Pro Hac Vice Appearance of Attorney Alan H. Pollack and Andrew J. Miller, filed by Mankind Pharma Ltd.. Signed by Judge Richard G. Andrews on 4/11/2023. (nms) (Entered: 04/11/2023) (0) |
| Apr 11, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Alan H. Pollack and Andrew J. Miller - filed by Mankind Pharma Ltd.. (Belgam, Neal) (Entered: 04/11/2023) (4) |
| Apr 11, 2023 | 16 | REDACTED VERSION of 9 Answer to Complaint and Counterclaims, by Mankind Pharma Ltd.. (Attachments: # 1 Exhibits A-C)(Belgam, Neal) Modified on 4/11/2023 (nms). (Entered: 04/11/2023) (Exhibit A - C) (30) |
| Apr 4, 2023 | 14 | ORAL ORDER: The redacted filing (D.I. 13 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document or part of a document that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 4/4/2023. (nms) (Entered: 04/04/2023) (0) |
| Apr 3, 2023 | 13 | REDACTED VERSION of 9 Answer to Complaint, and Counterclaims, by Mankind Pharma Ltd.. (Attachments: # 1 Exhibits A-C)(Belgam, Neal) Modified on 4/4/2023 (nms). (Entered: 04/03/2023) (Main Document) (26) |
| Apr 3, 2023 | 12 | NOTICE of Appearance by Daniel Taylor on behalf of Mankind Pharma Ltd. (Taylor, Daniel) (Entered: 04/03/2023) (1) |
| Apr 3, 2023 | 13 | REDACTED VERSION of 9 Answer to Complaint, and Counterclaims, by Mankind Pharma Ltd.. (Attachments: # 1 Exhibits A-C)(Belgam, Neal) Modified on 4/4/2023 (nms). (Entered: 04/03/2023) (Exhibit A - C) (24) |
| Mar 29, 2023 | 11 | NOTICE of Appearance by Jack B. Blumenfeld and Jeremy A. Tigan on behalf of AbbVie Inc., Allergan, Inc. (Blumenfeld, Jack) Modified on 3/30/2023 (nms). (Entered: 03/29/2023) (3) |
| Mar 27, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Mankind Pharma Ltd.. (Belgam, Neal) (Entered: 03/27/2023) (1) |
| Mar 27, 2023 | 9 | [SEALED] ANSWER to 1 Complaint, with Separate Defenses, and COUNTERCLAIM against All Plaintiffs by Mankind Pharma Ltd.. (Attachments: # 1 Exhibits A-C)(Belgam, Neal) Modified on 3/28/2023 (nms). (Entered: 03/27/2023) (0) |
| Mar 17, 2023 | 8 | WAIVER OF SERVICE returned executed by Allergan, Inc., AbbVie Inc.: For Mankind Pharma Ltd. waiver sent on 3/15/2023, answer due 5/15/2023. (Whitesell, Angela) (Entered: 03/17/2023) (1) |
| Mar 16, 2023 | N/A | Pro Hac Vice Attorney Michael A. Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen A. Scordino, Stephanie M. Piper, Henry Fildes, and Catherine Huang for AbbVie Inc. and Allergan, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 03/16/2023) (0) |
| Mar 16, 2023 | N/A | SO ORDERED, re 7 MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang, filed by Allergan, Inc., AbbVie Inc.. Signed by Judge Richard G. Andrews on 3/16/2023. (nms) (Entered: 03/16/2023) (0) |
| Mar 15, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (nms) (Entered: 03/15/2023) (0) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Main Document) (2) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Text of Proposed Order) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Michael Sitzman) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Ferlillia Roberson) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Susan Krumplitsch) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Ellen Scordino) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Stephanie Piper) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Henry Fildes) (1) |
| Mar 15, 2023 | 7 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Ferlillia V. Roberson, Susan Krumplitsch, Ellen Scordino, Stephanie Piper, Henry R. Fildes, and Catherine Huang - filed by AbbVie Inc., Allergan, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Ferlillia Roberson, # 4 Certification of Susan Krumplitsch, # 5 Certification of Ellen Scordino, # 6 Certification of Stephanie Piper, # 7 Certification of Henry Fildes, # 8 Certification of Catherine Huang)(Whitesell, Angela) (Entered: 03/15/2023) (Certification of Catherine Huang) (1) |
| Mar 13, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AbbVie for Allergan, Inc. filed by AbbVie Inc., Allergan, Inc. (vfm) (Entered: 03/14/2023) (2) |
| Mar 13, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,851,504. (vfm) (Entered: 03/14/2023) (1) |
| Mar 13, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 01/30/2023. Date of Expiration of Patent: 06/13/2027.Thirty Month Stay Deadline: 7/30/2025. (vfm) (Entered: 03/14/2023) (1) |
| Mar 13, 2023 | 6 | Summons Issued as to Mankind Pharma Ltd. on 3/13/2023. (Attachments: # 1 Summons Issued)(vfm) (Entered: 03/14/2023) (Summons Issued) (2) |
| Mar 13, 2023 | 1 | COMPLAINT for Patent Infringement filed against Mankind Pharma Ltd. (Filing fee $ 402, receipt number ADEDC-4088435) - filed by Allergan, Inc., AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet) (vfm) Modified on 3/15/2023 (nms). (Entered: 03/14/2023) (Exhibit A) (4) |
| Mar 13, 2023 | 1 | COMPLAINT for Patent Infringement filed against Mankind Pharma Ltd. (Filing fee $ 402, receipt number ADEDC-4088435) - filed by Allergan, Inc., AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet) (vfm) Modified on 3/15/2023 (nms). (Entered: 03/14/2023) (Exhibit B) (7) |
| Mar 13, 2023 | 1 | COMPLAINT for Patent Infringement filed against Mankind Pharma Ltd. (Filing fee $ 402, receipt number ADEDC-4088435) - filed by Allergan, Inc., AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet) (vfm) Modified on 3/15/2023 (nms). (Entered: 03/14/2023) (Civil Cover Sheet) (2) |
| Mar 13, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 03/14/2023) (3) |
| Mar 13, 2023 | 6 | Summons Issued as to Mankind Pharma Ltd. on 3/13/2023. (Attachments: # 1 Summons Issued)(vfm) (Entered: 03/14/2023) (Main Document) (2) |
| Mar 13, 2023 | 1 | COMPLAINT for Patent Infringement filed against Mankind Pharma Ltd. (Filing fee $ 402, receipt number ADEDC-4088435) - filed by Allergan, Inc., AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet) (vfm) Modified on 3/15/2023 (nms). (Entered: 03/14/2023) (Main Document) (10) |
